RESCEU

The RESCEU project aimed to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, regulatory agencies and industry; and provide infrastructure to perform future pivotal trials for RSV vaccines and therapeutics.

Human Respiratory Syncytial Virus (RSV) causes severe disease in the very young, elderly and in high risk groups. We have estimated that RSV was associated with 34 million cases of acute lower respiratory tract infection (ALRI), 3.4 million ALRI hospitalisations and 55,000 to 199,000 deaths in children <5 years in 2005.

RESCEU’s vision is to integrate and exploit existing knowledge and data to provide greater insights into the impact of RSV on health systems and societies throughout Europe, and to actively engage stakeholders in order to improve strategic planning and decision-making. It also seeks to access existing clinically annotated biological specimens from prospective studies and to supplement this with bespoke clinical studies to create a powerful new bio-repository for future research.

Project ID

Start date: 1 January 2017

End date: 31 December 2021

Grant agreement number: 116019

Project coordinator: The University of Edinburgh 

Project leader: Sanofi

Contributions

Total Costs: 29.171.790 €

IMI 2 JU Funding: 14.498.125 €

EFPIA in kind:  14.291.165 €

EFPIA in Cash: 518.500 €

Acknowledgement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement Nº 116019. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.